Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Maintenance in DLBCL After ASCT
NCT04799314Phase 3Unknown
- Sponsor
- Ruijin Hospital
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04799314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04799314.